Mostrar el registro sencillo del ítem

dc.contributor.authorNgo, Binh T.
dc.contributor.authorMarik, Paul
dc.contributor.authorKory, Pierre
dc.contributor.authorShapiro, Leland
dc.contributor.authorThomadsen, Raphael
dc.contributor.authorIglesias, Jose
dc.contributor.authorDitmore, Stephen
dc.contributor.authorRendell, Marc
dc.contributor.authorVaron, Joseph
dc.contributor.authorDube, Michael
dc.contributor.authorNanda, Neha
dc.contributor.authorIn, Gino K.
dc.contributor.authorArkfeld, Daniel
dc.contributor.authorChaudhary, Preet
dc.contributor.authorCampese, Vito M.
dc.contributor.authorHanna, Diana L.
dc.contributor.authorSawcer, David E.
dc.contributor.authorEhresmann, Glenn
dc.contributor.authorPeng, David
dc.contributor.authorSmorgorzewski, Miroslaw
dc.contributor.authorArmstrong, April
dc.contributor.authorDasgupta, Rajkumar
dc.contributor.authorSattler, Fred R.
dc.contributor.authorBrennan-Rieder, Denise
dc.contributor.authorMussini, Cristina
dc.contributor.authorMitjà, Oriol
dc.contributor.authorSoriano, Vicente (1)
dc.contributor.authorPeschanski, Nicolas
dc.contributor.authorHayem, Gilles
dc.contributor.authorConfalonieri, Marco
dc.contributor.authorPiccirillo, Maria Carmela
dc.contributor.authorLobo-Ferreira, António
dc.contributor.authorBello Rivero, Iraldo
dc.contributor.authorTurkia, Mika
dc.contributor.authorVinjevoll, Eivind H.
dc.contributor.authorGriffin, Daniel O.
dc.contributor.authorHung, Ivan Fn
dc.date2021
dc.date.accessioned2021-11-29T10:33:02Z
dc.date.available2021-11-29T10:33:02Z
dc.identifier.issn1354-3784
dc.identifier.urihttps://reunir.unir.net/handle/123456789/12163
dc.description.abstractBackground: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy relies solely on vaccines to prevent disease.Methods: We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results.Results: As of 2/15/2021, we found 111 publications reporting findings on 14 classes of agents, and 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care. Remdesivir and high titer convalescent plasma have emergency use authorization for hospitalized patients in the U.S.A. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. Monoclonal antibodies are authorized for outpatients, but supply is inadequate to treat all at time of diagnosis. Favipiravir, ivermectin, and interferons are approved in certain countries.Expert Opinion: Vaccines and antibodies are highly antigen specific, and new SARS-Cov-2 variants are appearing. We call on public health authorities to authorize treatments with known low-risk and possible benefit for outpatients in parallel with universal vaccination.es_ES
dc.language.isoenges_ES
dc.publisherExpert opinion on investigational drugses_ES
dc.relation.ispartofseries;vol. 30, nº 5
dc.relation.urihttps://www.tandfonline.com/doi/full/10.1080/13543784.2021.1901883es_ES
dc.rightsopenAccesses_ES
dc.subjectSARS-Cov-2es_ES
dc.subjectcovid-19es_ES
dc.subjecthcqes_ES
dc.subjectremdesivires_ES
dc.subjectfavipiravires_ES
dc.subjectinterferon-λes_ES
dc.subjectinterferon-βes_ES
dc.subject-1es_ES
dc.subjectconvalescent plasmaes_ES
dc.subjectsynthetic anti-spike protein antibodieses_ES
dc.subjectivermectines_ES
dc.subjectWOS(2)es_ES
dc.subjectScopuses_ES
dc.titleThe time to offer treatments for COVID-19es_ES
dc.typearticlees_ES
reunir.tag~ARIes_ES
dc.identifier.doihttps://doi.org/10.1080/13543784.2021.1901883


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem